



ASX AND MEDIA RELEASE

Leading oncologist joins Race scientific team

19 August 2016, Perth, Australia: Race Oncology Ltd (ASX: RAC) today announced that it had signed an agreement with European oncologist, Dr Rudolf Steiner, under which he will be the Company's key scientific and clinical affairs advisor in Europe. Dr Steiner will assist Race Oncology in developing clinical protocols for further studies in the US on Bisantrene and provide technical oversight for the Company's Named Patient sales program in Europe.

"I am excited to work with Race Oncology and assist the company in positioning Bisantrene within the modern treatment of AML and other cancers," said Dr Steiner.

"Dr Steiner is an eminent oncologist and we are delighted to have him on board as a scientific advisor," said Race Oncology CEO, Peter Molloy.

Rudolf Steiner MD is a Swiss medical oncologist who trained at Zurich University Hospital and later worked at the ICRF Clinical Oncology Unit at Guy's Hospital London and at Cancer Research UK. He completed his training in haematological oncology in London and then worked for Ciba-Geigy (now Novartis) in Switzerland, where he was responsible for the company's phase I and IIa clinical studies in oncology and helped to shape the preclinical and early clinical portfolio of the company. He later returned to clinical practice at the St. Gallen Comprehensive Cancer Center and Zurich University Hospital. During his career, he has initiated and guided several clinical study programs that have resulted in approved cancer drugs. He has a strong interest in anthracycline-associated cardiotoxicity and is an editorial board member of the recently created online journal *Cardio-Oncology*, which focuses on the growing problem of cardiotoxicity associated with various cancer drugs.

"Cardiotoxicity has been a problem with a number of frequently used cancer drugs," said Dr Rothman, Race Chief Scientific Officer. "Bisantrene's lack of cardiotoxicity makes it even more relevant today than when the drug was first developed and it opens the door to favourable combinations of Bisantrene with other cancer drugs. Moreover, Bisantrene's immunological activity makes it ideal for combination use with the newer immunotherapies."

About Race Oncology

Race Oncology Ltd is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company's goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit raceoncology.com for more information.

For more information, contact: **Peter Molloy**
Managing Director
T: +61 (0) 3 9097 1656
M: +61 (0) 418 174 816